Pharmena S.A. (WAR:PHR) — Market Cap & Net Worth
Market Cap & Net Worth: Pharmena S.A. (PHR)
Pharmena S.A. (WAR:PHR) has a market capitalization of $9.53 Million (zł34.64 Million) as of September 17, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #27274 globally and #292 in its home market, demonstrating a -3.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmena S.A.'s stock price zł3.11 by its total outstanding shares 11137758 (11.14 Million). Also see Pharmena S.A. asset portfolio for a full breakdown of the balance sheet.
Pharmena S.A. Market Cap History: 2015 to 2026
Pharmena S.A.'s market capitalization history from 2015 to 2026. Data shows change from $64.31 Million to $9.53 Million (-14.29% CAGR). Also see Pharmena S.A. operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Pharmena S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmena S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Pharmena S.A. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
43.81x
Pharmena S.A.'s market cap is 43.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $64.31 Million | $17.47 Million | -$3.62 Million | 3.68x | N/A |
| 2016 | $48.84 Million | $15.91 Million | -$1.66 Million | 3.07x | N/A |
| 2017 | $59.30 Million | $12.51 Million | -$2.39 Million | 4.74x | N/A |
| 2018 | $18.39 Million | $13.04 Million | -$444.00K | 1.41x | N/A |
| 2019 | $14.82 Million | $11.10 Million | -$9.57 Million | 1.34x | N/A |
| 2020 | $24.89 Million | $9.93 Million | -$6.89 Million | 2.51x | N/A |
| 2021 | $21.88 Million | $15.21 Million | -$4.59 Million | 1.44x | N/A |
| 2022 | $15.49 Million | $299.00K | -$1.57 Million | 51.80x | N/A |
| 2023 | $19.64 Million | $9.84 Million | $28.94 Million | 2.00x | 0.68x |
| 2024 | $11.74 Million | $268.00K | -$1.26 Million | 43.81x | N/A |
Competitor Companies of PHR by Market Capitalization
Companies near Pharmena S.A. in the global market cap rankings as of September 17, 2026. Review Pharmena S.A. tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pharmena S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Pharmena S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharmena S.A.'s market cap moved from $64.31 Million to $ 9.53 Million, with a yearly change of -14.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł9.53 Million | +19.62% |
| 2025 | zł7.97 Million | -32.11% |
| 2024 | zł11.74 Million | -40.22% |
| 2023 | zł19.64 Million | +26.78% |
| 2022 | zł15.49 Million | -29.20% |
| 2021 | zł21.88 Million | -12.11% |
| 2020 | zł24.89 Million | +67.91% |
| 2019 | zł14.82 Million | -19.40% |
| 2018 | zł18.39 Million | -68.99% |
| 2017 | zł59.30 Million | +21.42% |
| 2016 | zł48.84 Million | -24.05% |
| 2015 | zł64.31 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Pharmena S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.53 Million USD |
| MoneyControl | $9.53 Million USD |
| MarketWatch | $9.53 Million USD |
| marketcap.company | $9.53 Million USD |
| Reuters | $9.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharmena S.A.
Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including face, hair, and body care products, as well as dietary supplement. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. Pharmena S.A. was founded in 2002 and is based in Lódz… Read more